West of Scotland Regional Heart & Lung Centre, Golden Jubilee National Hospital, Glasgow, UK.
Biomark Med. 2011 Feb;5(1):9-30. doi: 10.2217/bmm.11.2.
Dual antiplatelet therapy with aspirin and clopidogrel is recommended in all patients who have had an acute coronary syndrome or who undergo percutaneous coronary intervention to prevent further ischemic events. Resistance or reduced responsiveness to aspirin and/or clopidogrel has been associated with adverse cardiovascular outcomes, including stent thrombosis. There have been significant advances in this field, which aim to overcome antiplatelet resistance, including the development of new antiplatelet agents. The rationale for dual antiplatelet therapy, the impact of suboptimal efficacy and the potential ways of overcoming resistance or variability in response to antiplatelet agents will be reviewed in this article.
双重抗血小板治疗，即阿司匹林联合氯吡格雷，推荐用于所有发生急性冠脉综合征或行经皮冠状动脉介入治疗的患者，以预防进一步的缺血事件。阿司匹林和/或氯吡格雷抵抗或反应性降低与不良心血管结局相关，包括支架血栓形成。该领域取得了显著进展，旨在克服抗血小板抵抗，包括新型抗血小板药物的开发。本文将综述双重抗血小板治疗的原理、治疗效果不理想的影响，以及克服抗血小板药物抵抗或反应性差异的潜在方法。
